PAINCAGE
"The NGF system and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain"
| Coordinatore | SCUOLA NORMALE SUPERIORE DI PISA
Organization address
address: Piazza dei Cavalieri 7 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 7˙878˙342 € |
| EC contributo | 5˙860˙831 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-04-01 - 2017-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SCUOLA NORMALE SUPERIORE DI PISA
Organization address
address: Piazza dei Cavalieri 7 contact info |
IT (Pisa) | coordinator | 1˙159˙329.00 |
| 2 |
EUROPEAN BRAIN RESEARCH INSTITUTE R ITA LEVI-MONTALCINI FONDAZIONE*EBRI
Organization address
address: Via del Fosso di Fiorano 64 contact info |
IT (ROMA) | participant | 837˙898.00 |
| 3 |
AARHUS UNIVERSITET
Organization address
address: Nordre Ringgade 1 contact info |
DK (AARHUS C) | participant | 776˙000.00 |
| 4 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 710˙215.00 |
| 5 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 610˙214.00 |
| 6 |
GENOMNIA SRL
Organization address
address: CORSO MAGENTA 56 contact info |
IT (MILANO) | participant | 505˙143.00 |
| 7 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 498˙384.00 |
| 8 |
UNIVERSIDAD DE SALAMANCA
Organization address
address: "Patio de Escuelas, 1" contact info |
ES (SALAMANCA) | participant | 492˙314.00 |
| 9 |
LEVICEPT LTD
Organization address
address: RAMSGATE ROAD DISCOVERY PARK INNOVATION HOUSE contact info |
UK (SANDWICH KENT) | participant | 271˙334.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'So far, there are no effective treatments for neuropathic pain (NP), and current treatments suffer from serious unwanted side effects. The NGF ligand-receptor system has recently emerged as a novel target for NP of great therapeutic potential, a master regulator, controlling both neuropathic and inflammatory components. Besides being a multi-component system, it also modulates the endocannabinoid (EC) signalling. Blocking the NGF signaling system is therefore a rational and thoroughly validated approach to pain therapy. Extensive evidence for potent analgesic efficacy of antiNGF mAbs has been obtained in preclinical models and in clinical trials,showing remarkable analgesic efficacy and creating great expectations for this new class of analgesic compounds.However, potential safety concerns related to off-target side effects have been raised and recently the FDA called for more preclinical research. To fully exploit the huge therapeutic potential of NGF system, we built a consortium of leading researchers in the NGF, EC and pain scientific arena.The innovative proposal will investigate new strategies for the treatment of different NP forms, based on the NGF system and its interplay with EC signalling, focussing at different levels of the pain transmission and perception systems. The project results will provide solid, mechanism-based grounds for the development of already identified second-generation therapeutics, based on the “NGF target” system, as well as for the identification and validation of new druggable targets emerging from the elucidated mechanisms. It will also identify biomarkers for NP, validated in animal models and clinical samples, that could result in future clinical benefits, for the stratification of patients suffering from different neuropathies and their treatment. The project will contribute to the understanding and controlling NP mechanisms, with an interdisciplinary approach, leading to the development of next-generation NGF targeting drugs.'